朱曲波，1981年1月生，巴黎人官方网站，巴黎人官方网站药剂学系，副教授。
朱曲波博士，湖南长沙人。2003年本科毕业于武汉大学；2009年博士毕业于美国Texas A&M University；并在美国Case Western Reserve University知名教授Krzysztof Palczewski实验室从事博士后研究工作。2011年以升华猎英计划引入巴黎人官方网站药学院，担任副教授。研究方向包括：1、非编码RNA在癌症及神经系统疾病中的功能研究；2、核酸及蛋白质等生物大分子的检测；3、抗癌药物的动力学研究等。获得国家自然科学基金、湖南省自然科学基金等多项经费支持。其科研成果受到了国内及国际同行的认可，在相关领域发表论文30多篇；其中包括Biosensors & Bioelectronics,、Journal of Cell Biology、Oncogene、Cancer Letters等国际权威期刊，论文被引次数超过 1000次，影响h 指数达 15。获得国家发明专利4项。2018年荣获湖南省青年骨干教师称号，2022年获得湖南省杰出青年基金项目。朱曲波积极参与学院及社会的各项工作。2013年以来，一直担任巴黎人官方网站青年科协副主席，主办了多项学术活动；2017-2021年担任药学院教授委员会副主任委员，积极参与学院的招生、评审及调研工作。此外，朱曲波副教授是中国细胞生物学会会员，中国药理学会会员，湖南省肿瘤药理学会委员，积极参与各项学术活动，为学科发展贡献力量。
受教育经历：
2003/12 –2009/05，Texas A&M University，生物科学及技术研究所，博士
1999/09 –2003/07，武汉大学，生科院药学系，学士
研究工作经历：
2011/09 –至今， 巴黎人官方网站，药学院药剂学系，副教授
2009/08 –2011/09，Case Western Reserve University，药理学系，博士后
承担课题:
1. 校企联合创新项目，2022XQLH119，非线性杂交链式反应检测生物标志物的研究，2023/01-2024/12，10万，主持
2. 校企联合创新项目，2022XQLH120，基于适配体的非线性杂交链反应 DNA 纳米载体递送药物用于癌症治疗，2023/01-2024/12，10万，主持
3. 国家自然科学基金面上项目，32270609，CPSF3通过抑制circRNA生成诱导肝癌发生发展的机制研究，2023/01-2026/12，54万元，主持
4. 湖南省自然科学杰出青年基金项目，2022JJ10091，基于分支杂交链式反应与脱氧核酶的肿瘤非编码RNA检测及筛选，2022/01-2025/12，50万元，主持
5. 湖南省自然科学基金面上项目，2021JJ30916，CPSF30调节肝癌细胞中circRNA形成的机制研究，2021/01-2023/12，5万，主持
6. 赛尔博克斯生物科技有限公司，H202105180720001，支原体检测及清除试剂盒开发，2021/05-2023/12，32万，主持
7. 湖南省自然科学基金面上项目，2018JJ2493，NUDT21调控肝癌中AGO2介导的microRNA基因沉默机制研究，2018/01-2020/12，5万，主持
8. 巴黎人官方网站教师研究基金，502050003，实体癌中microRNA的调控机制研究，2016/01-2017/12，20万元，主持
9. 国家自然科学基金青年基金，31201056，miR-183/-96/-182基因簇对乳腺癌诊断及治疗作用的机制研究，2013/01-2015/12，23万元，主持
10. 国家自然科学基金面上项目，81273585，补肺活血胶囊治疗COPD物质基础及作用机制研究，2013/01-2016/12，65万元，参加
11. 巴黎人官方网站，2012QNZT091，青年教师助推，2012/01-2013/12，10万元，主持
12. 巴黎人官方网站，7601110179，升华猎英计划，2011/09-2016/09，50万元，主持
主要论文： 1-39
1 Zeng, Z. et al. Rational design of nonlinear hybridization immunosensor chain reactions for simultaneous ultrasensitive detection of two tumor marker proteins. Anal Methods 15, 1422-1430, doi:10.1039/d2ay01941h (2023).
2 Hu, Y. et al. Trehalose in Biomedical Cryopreservation-Properties, Mechanisms, Delivery Methods, Applications, Benefits, and Problems. ACS Biomater Sci Eng 9, 1190-1204, doi:10.1021/acsbiomaterials.2c01225 (2023).
3 Dong, J. et al. Challenges and opportunities for circRNA identification and delivery. Crit Rev Biochem Mol Biol, 1-17, doi:10.1080/10409238.2023.2185764 (2023).
4 Cao, X., Chen, C. & Zhu, Q. Biosensors based on functional nucleic acids and isothermal amplification techniques. Talanta 253, 123977, doi:10.1016/j.talanta.2022.123977 (2023).
5 Zeng, Z. et al. Nonlinear hybridization chain reaction-based flow cytometric immunoassay for the detection of prostate specific antigen. Anal Chim Acta 1220, 340048, doi:10.1016/j.aca.2022.340048 (2022).
6 Ouyang, Q. et al. New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease. Journal of Drug Targeting 30, 61-81, doi:10.1080/1061186x.2021.1927055 (2022).
7 Ouyang, Q. et al. Brain-Penetration and Neuron-Targeting DNA Nanoflowers Co-Delivering miR-124 and Rutin for Synergistic Therapy of Alzheimer's Disease. Small 18, doi:10.1002/smll.202107534 (2022).
8 Liu, K. et al. Age-related Loss of miR-124 Causes Cognitive Deficits via Derepressing RyR3 Expression. Aging and Disease, doi:10.14336/ad.2022.0204 (2022).
9 Cao, X., Chen, C. & Zhu, Q. Biosensors based on functional nucleic acids and isothermal amplification techniques. Talanta 253, 123977, doi:10.1016/j.talanta.2022.123977 (2022).
10 Zhou, R. et al. Traditional and new applications of the HCR in biosensing and biomedicine. Analyst 146, 7087-7103, doi:10.1039/d1an01371h (2021).
11 Zeng, Z. et al. Nonlinear hybridization chain reaction-based functional DNA nanostructure assembly for biosensing, bioimaging applications. Biosensors & Bioelectronics 173, doi:10.1016/j.bios.2020.112814 (2021).
12 Wang, X., Dong, J., Li, X., Cheng, Z. & Zhu, Q. CPSF4 regulates circRNA formation and microRNA mediated gene silencing in hepatocellular carcinoma. Oncogene 40, 4338-4351, doi:10.1038/s41388-021-01867-6 (2021).
13 Su, Y. et al. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Delivery 28, 1397-1418, doi:10.1080/10717544.2021.1938756 (2021).
14 Liu, X. et al. The Feasibility of Antioxidants Avoiding Oxidative Damages from Reactive Oxygen Species in Cryopreservation. Frontiers in Chemistry 9, doi:10.3389/fchem.2021.648684 (2021).
15 Liu, X. et al. Methods in Biosynthesis and Characterization of the Antifreeze Protein (AFP) for Potential Blood Cryopreservation. Journal of Nanomaterials 2021, doi:10.1155/2021/9932538 (2021).
16 Liu, X. et al. A Review of the Material Characteristics, Antifreeze Mechanisms, and Applications of Cryoprotectants (CPAs). Journal of Nanomaterials 2021, doi:10.1155/2021/9990709 (2021).
17 Huang, Y. & Zhu, Q. Mechanisms Regulating Abnormal Circular RNA Biogenesis in Cancer. Cancers 13, doi:10.3390/cancers13164185 (2021).
18 Dong, J. et al. Specific and sensitive detection of CircRNA based on netlike hybridization chain reaction. Biosensors & Bioelectronics 192, doi:10.1016/j.bios.2021.113508 (2021).
19 Dong, J., Cheng, Z., Tan, S. & Zhu, Q. Clay nanoparticles as pharmaceutical carriers in drug delivery systems. Expert Opinion on Drug Delivery 18, 695-714, doi:10.1080/17425247.2021.1862792 (2021).
20 Li, X., Wang, X., Cheng, Z. & Zhu, Q. AGO2 and its partners: a silencing complex, a chromatin modulator, and new features. Critical Reviews in Biochemistry and Molecular Biology 55, 33-53, doi:10.1080/10409238.2020.1738331 (2020).
21 Li, X., Ding, J., Wang, X., Cheng, Z. & Zhu, Q. NUDT21 regulates circRNA cyclization and ceRNA crosstalk in hepatocellular carcinoma. Oncogene 39, 891-904, doi:10.1038/s41388-019-1030-0 (2020).
22 Li, F. et al. In vitrometabolic characterization of orbitazine, a novel derivative of the PAC-1 anticancer agent. Journal of Pharmacy and Pharmacology 72, 1199-1210, doi:10.1111/jphp.13296 (2020).
23 Ding, J. et al. Tandem DNAzyme for double digestion: a new tool for circRNA suppression. Biological Chemistry 400, 247-253, doi:10.1515/hsz-2018-0232 (2019).
24 Sun, M. et al. NUDT21 regulates 3 '-UTR length and microRNA-mediated gene silencing in hepatocellular carcinoma. Cancer Letters 410, 158-168, doi:10.1016/j.canlet.2017.09.026 (2017).
25 Chen, Y.-f. et al. Inhibitory effect of SM-1 on human liver microsomal cytochrome P450 enzyme. Chinese Pharmacological Bulletin 33, 627-629, doi:10.3969/j.issn.10011978.2017.05.008 (2017).
26 Yin, Y., Shen, C., Xie, P., Cheng, Z. & Zhu, Q. Construction of an initial microRNA regulation network in breast invasive carcinoma by bioinformatics analysis. Breast 26, 1-10, doi:10.1016/j.breast.2015.11.008 (2016).
27 Huang, L. et al. Simotinib as a modulator of P-glycoprotein: substrate, inhibitor, or inducer? Anti-Cancer Drugs 27, 300-311, doi:10.1097/cad.0000000000000332 (2016).
28 Duan, Q. et al. Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation. Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms 1859, 564-571, doi:10.1016/j.bbagrm.2016.02.004 (2016).
29 Chen, Y., Sun, M., Ding, J. & Zhu, Q. SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis. Cancer Chemotherapy and Pharmacology 78, 643-654, doi:10.1007/s00280-016-3115-6 (2016).
30 Zhang, H. et al. PABPC1 interacts with AGO2 and is responsible for the microRNA mediated gene silencing in high grade hepatocellular carcinoma. Cancer Letters 367, 49-57, doi:10.1016/j.canlet.2015.07.010 (2015).
31 Zhu, Q., Liu, Z., Li, P. & Cheng, Z. Drug Interaction Studies Reveal That Simotinib Upregulates Intestinal Absorption by Increasing the Paracellular Permeability of Intestinal Epithelial Cells. Drug Metabolism and Pharmacokinetics 29, 317-324, doi:10.2133/dmpk.DMPK-13-RG-123 (2014).
32 Li, P. et al. MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Research 16, doi:10.1186/s13058-014-0473-z (2014).
33 Zhu, Q., Sun, W. & Palczewski, K. Sponge Transgenic Mouse Model Reveals the Important Roles of Mir-183 Cluster in Retina. ARVO Annual Meeting Abstract Search and Program Planner 2011, 507-507 (2011).
34 Zhu, Q. et al. Sponge Transgenic Mouse Model Reveals Important Roles for the MicroRNA-183 (miR-183)/96/182 Cluster in Postmitotic Photoreceptors of the Retina. Journal of Biological Chemistry 286, 31749-31760, doi:10.1074/jbc.M111.259028 (2011).
35 Meng, L., Hsu, J. K., Zhu, Q., Lin, T. & Tsai, R. Y. L. Nucleostemin inhibits TRF1 dimerization and shortens its dynamic association with the telomere. Journal of Cell Science 124, 3706-3714, doi:10.1242/jcs.089672 (2011).
36 Zhu, Q. et al. GNL3L stabilizes the TRF1 complex and promotes mitotic transition. Journal of Cell Biology 185, 827-839, doi:10.1083/jcb.200812121 (2009).
37 Yasumoto, H., Meng, L., Lin, T., Zhu, Q. & Tsai, R. Y. L. GNL3L inhibits activity of estrogen-related receptor gamma by competing for coactivator binding. Journal of Cell Science 120, 2532-2543, doi:10.1242/jcs.009878 (2007).
38 Meng, L., Zhu, Q. & Tsai, R. Y. L. Nucleolar trafficking of nucleostemin family proteins: Common versus protein-specific mechanisms. Molecular and Cellular Biology 27, 8670-8682, doi:10.1128/mcb.00635-07 (2007).
39 Zhu, Q., Yasumoto, H. & Tsai, R. Y. L. Nucleostemin delays cellular senescence and negatively regulates TRF1 protein stability. Molecular and Cellular Biology 26, 9279-9290, doi:10.1128/mcb.00724-06 (2006).
获批专利:
(1) 朱曲波；陈传品；董佳妮；一种基于网状杂交链式反应的基因链检测方法，2021-8-5，中国，CN202110897288.7 (专利)
(2) 朱曲波；李大力；童建斌；殷永佳；miR-124基因敲除小鼠动物模型的构建方法和应用，2019-1-22，中国，ZL201610669402.X (专利)
(3) 童建斌；欧阳文；周文虎；朱曲波；欧阳琴；刘凯；一种基因/小分子化合物纳米递药系统及其制备方法与应用，2022-01-28，中国，CN202111248086.6 (专利)
承担课程
课程名称 |
授课对象 |
学生数 |
承担学时 |
总学时 |
生物药剂学与药物动力学实验 |
本科生 |
120 |
48 |
48 |
药物分析A |
本科生 |
120 |
36 |
54 |
药学英语 |
本科生 |
120 |
16 |
32 |
药物分析实验 |
本科生 |
120 |
58 |
58 |
药物分析B |
本科生 |
30 |
16 |
32 |
药物分析应用技术 |
研究生 |
20 |
12 |
24 |
现代药学评价方法 |
研究生 |
30 |
3 |
32 |
药剂学研究进展 |
博士生 |
5 |
4 |
32 |
获奖：
(1) 朱曲波(1/1); 湖南省杰出青年, 湖南省科技厅, 2022
(2) 朱曲波(1/1); 湖南省青年骨干教师, 湖南省教育厅, 2018
(3) 朱曲波(1/1); 西南铝优秀教师奖, 西南铝业有限责任公司, 2016
(4) 朱曲波(1/1); 升华猎英计划, 巴黎人官方网站, 2011
